Apimeds Pharmaceuticals US, Inc. APUS
7.25
2.33
47.36%
as of 25 Sep
- Market cap
- $7.6M
- P/E
- 0.0×
Follow APUS
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Current Ratio |
1.31 | 0.01 | 3.42 |
Net Debt/EBITDA |
0.38 | (0.27) | 0.19 |
Debt/Assets |
4.32% | 2,647.33% | 63.23% |
Debt/Equity |
0.05 | (0.26) | 8.37 |
Asset Turnover |
0.00 | 0.00 | — |
Operating CF/Net income |
1.49 | 0.53 | 0.81 |
Capex/Depreciation |
(10.05) | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| (7.90%) | 209.62% | 0.00% | |
| (7.31%) | (638.79%) | 0.00% | |
ROIC |
(5.00%) | 0.00% | 0.00% |
Return on Tangible Assets |
(180.27%) | 137.46% | (260.27%) |
Research and Development Expense of Revenue |
0.00% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.91 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% |
Free Cash Flow per Share |
(8.25) | (0.93) | (1.37) |
Cash per Share |
10.69 | 0.00 | 0.89 |
Shareholders Equity per Share |
140.92 | (1.72) | 0.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
140.92 | (1.72) | 0.07 |
Free Cash Flow |
(8.98) | (0.73) | (0.63) |
Working Capital |
3.28 | (1.01) | 0.30 |
Capital Expenditures |
(0.06) | — | — |
Net Current Asset Value |
3.15 | (1.36) | 0.03 |
| Other line items | |||
Quick Ratio |
1.09 | 0.00 | 3.33 |
Depreciation/Fixed assets |
0.11 | — | — |
Cash ROIC |
(5.22%) | 72.78% | (88.51%) |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(8.20) | (0.93) | (1.37) |
Capex per Share |
(0.05) | 0.00 | 0.00 |
Average Payables |
0.75 | 0.32 | — |
Average Assets |
82.10 | 0.22 | — |
Average Common Equity |
75.96 | (0.66) | — |
Capex to Sales |
0.00 | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% |
Columns are period end dates